CDKL5 and craniodiaphyseal dysplasia: It has been shown to effectively control seizures in multiple animal models and has recently been approved by the FDA in the US for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older3.